4
Changes in Ownership
BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-044861
CEO and President sold 5,268 shares at an average $2.62 ($13,823)
- CEO and President acquired 16,610 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Mehta Vimal · CEO and President
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-03-14 | Exercise or conversion : show line 1 in the form 10b5-1 | +2,610 | 34,832 | D | ||
| 2024-03-15 | Exercise or conversion : show line 2 in the form 10b5-1 | +14,000 | 48,832 | D | ||
| 2024-04-04 | Sale : show line 3 in the form 10b5-1 | −829 | $2.62 | $2,172 | 48,003 | D |
| 2024-04-04 | Sale : show line 4 in the form 10b5-1 | −4,439 | $2.62 | $11,651 | 43,564 | D |
| Open-market sales · 5,268 sh · avg $2.62 · $13,823 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-03-14 | Exercise or conversion : show line 5 in the form 10b5-1 Restricted Stock Units | −2,610 | 20,875 | D |
| 2024-03-15 | Exercise or conversion : show line 6 in the form 10b5-1 Restricted Stock Units | −14,000 | 42,000 | D |
Loading xslF345X05/tm2411220-5_4seq1.xml…